Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALE.P02

PreclinicalSmall molecule

AAlentis Therapeutics AG

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Squamous Non-Small-Cell Lung CancerRecruiting

Squamous Non-Small-Cell Lung CancerPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Squamous Non-Small-Cell Lung Cancer

NCT06747585

Clinical

Trials by Indication[1]

Squamous Non-small-cell Lung Cancer1 trial

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

Recruiting·AAlentis Therapeutics AG·Preclinical·NCT06747585·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALE.P02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE.P02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE.P02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alentis Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlentis Therapeutics AG

Related News